全球首个这个“温江造”靶向药第三项适应症获批

动脉网
Oct 15

四川科伦博泰的靶向药芦康沙妥珠单抗(sac-TMT,佳泰莱®)获国家药品监督管理局批准第三项适应症,用于治疗经EGFR-TKI治疗后进展的EGFR基因突变阳性的局部晚期或转移性非鳞状非小细胞肺癌成人患者。该药是迄今全球首个且唯一对比含铂双药化疗显示显著总生存期获益,并获批用于仅接受过TKI治疗后进展的晚期NSCLC的ADC药物。作为科伦博泰核心产品,sac-TMT是全球首个在肺癌适应症获批上市的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10